ATE269414T1 - Verfahren zur drogenuntersuchung - Google Patents

Verfahren zur drogenuntersuchung

Info

Publication number
ATE269414T1
ATE269414T1 AT96927362T AT96927362T ATE269414T1 AT E269414 T1 ATE269414 T1 AT E269414T1 AT 96927362 T AT96927362 T AT 96927362T AT 96927362 T AT96927362 T AT 96927362T AT E269414 T1 ATE269414 T1 AT E269414T1
Authority
AT
Austria
Prior art keywords
organism
reporter gene
cell
transcriptional
drug
Prior art date
Application number
AT96927362T
Other languages
English (en)
Inventor
Jasper Rine
Matthew Ashby
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24040680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE269414(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE269414T1 publication Critical patent/ATE269414T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96927362T 1995-08-09 1996-08-09 Verfahren zur drogenuntersuchung ATE269414T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/512,811 US5569588A (en) 1995-08-09 1995-08-09 Methods for drug screening
PCT/US1996/012956 WO1997006277A1 (en) 1995-08-09 1996-08-09 Methods for drug screening

Publications (1)

Publication Number Publication Date
ATE269414T1 true ATE269414T1 (de) 2004-07-15

Family

ID=24040680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927362T ATE269414T1 (de) 1995-08-09 1996-08-09 Verfahren zur drogenuntersuchung

Country Status (10)

Country Link
US (1) US5569588A (de)
EP (1) EP0791078B1 (de)
JP (1) JPH10507647A (de)
AT (1) ATE269414T1 (de)
AU (1) AU724474B2 (de)
CA (1) CA2202154C (de)
DE (1) DE69632716T2 (de)
DK (1) DK0791078T3 (de)
ES (1) ES2219692T3 (de)
WO (1) WO1997006277A1 (de)

Families Citing this family (349)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
GB9514184D0 (en) 1995-07-12 1995-09-13 Zeneca Ltd Assay
US6326140B1 (en) * 1995-08-09 2001-12-04 Regents Of The University Of California Systems for generating and analyzing stimulus-response output signal matrices
DE69712731T2 (de) 1996-01-26 2003-02-06 Virco Nv Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten
US6247995B1 (en) 1996-02-06 2001-06-19 Bruce Bryan Bioluminescent novelty items
JP2001503603A (ja) * 1996-04-01 2001-03-21 スクリプトゲン ファーマシューティカルズ インク カンディダ アルビカンスからの新規ｔａｔａ―結合タンパク質、それをコード化する核酸配列、及びカンディダ アルビカンス増殖の阻害のためのスクリーニング方法
US6280967B1 (en) 1996-08-02 2001-08-28 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time of cellular responses
US5804436A (en) * 1996-08-02 1998-09-08 Axiom Biotechnologies, Inc. Apparatus and method for real-time measurement of cellular response
US6558916B2 (en) 1996-08-02 2003-05-06 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time measurements of patient cellular responses
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US5955275A (en) * 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US6025485A (en) 1997-02-14 2000-02-15 Arcaris, Inc. Methods and compositions for peptide libraries displayed on light-emitting scaffolds
ATE284972T1 (de) * 1996-09-24 2005-01-15 Cadus Pharmaceutical Corp Verfahren und zusammensetzungen für die identifizierung von receptor effectoren
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
GB9622665D0 (en) * 1996-10-31 1997-01-08 Zeneca Ltd Methods
CA2271717A1 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6623922B1 (en) 1997-02-14 2003-09-23 Deltagen Proteomics Methods for identifying, characterizing, and evolving cell-type specific CIS regulatory elements
WO1998037235A1 (en) * 1997-02-24 1998-08-27 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6960457B1 (en) * 1997-09-04 2005-11-01 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US20070082356A1 (en) * 1997-09-24 2007-04-12 Cornell Research Foundation Inc., a New York, NY corporation Methods of evaluating transplant rejection
EP0969100A4 (de) * 1997-09-29 2005-03-16 Hsp Res Inst Inc Verfahren zur untersuchung von expression-induzierenden regulatoren von hitzeschockproteinen
AU1094699A (en) * 1997-10-15 1999-05-03 Diversa Corporation Screening for novel compounds which regulate biological interactions
EP1149920A1 (de) * 1997-10-15 2001-10-31 Diversa, Inc. Screening fÜr neue Verbindungen, die biologische Interaktionen regulieren
DE69829402T2 (de) * 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6905818B1 (en) 1997-11-27 2005-06-14 Max-Planck-Gesellschaft Zur Forderungder Wissenschaften Method for the identification and characterization of interacting molecules by automated interaction mating
ATE262178T1 (de) * 1997-11-27 2004-04-15 Max Planck Gesellschaft Identifizierung und charakterisierung von interagierenden molekülen
GB9726431D0 (en) * 1997-12-15 1998-02-11 Dower Steven Expression cloning and single cell detection of phenotype
US6046002A (en) * 1998-01-05 2000-04-04 The Board Of Trustees Of The Leland Stanford Junior University Highly parallel and sensitive method for identifying drugs and drug targets
US6699969B1 (en) 1998-04-14 2004-03-02 The Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
EP1071943A4 (de) 1998-04-14 2005-08-10 Univ California Test zum nachweis von mikrotubulus depolymerisierungshemmern
US6872537B1 (en) 1998-04-14 2005-03-29 Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US6324479B1 (en) 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
US5965352A (en) * 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
AU750975B2 (en) * 1998-05-12 2002-08-01 Rosetta Inpharmatics, Inc. Quantitative methods, systems and apparatuses for gene expression analysis
AU4196199A (en) * 1998-05-22 1999-12-13 Tufts University Mara family helix-turn-helix domains and their methods of use
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6132969A (en) * 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
IL140058A0 (en) * 1998-06-30 2002-02-10 Procter & Gamble Methods for inhibiting tef-3 activity
US6171794B1 (en) 1998-07-13 2001-01-09 Rosetta Inpharmatics, Inc. Methods for determining cross-hybridization
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
US6146830A (en) 1998-09-23 2000-11-14 Rosetta Inpharmatics, Inc. Method for determining the presence of a number of primary targets of a drug
CN1335892A (zh) * 1998-10-23 2002-02-13 耶鲁大学 植物组学;应用于草药组合物的以基因组为依据的方法
US6950752B1 (en) 1998-10-27 2005-09-27 Rosetta Inpharmatics Llc Methods for removing artifact from biological profiles
US6468476B1 (en) * 1998-10-27 2002-10-22 Rosetta Inpharmatics, Inc. Methods for using-co-regulated genesets to enhance detection and classification of gene expression patterns
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
US6801859B1 (en) 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
US6453241B1 (en) 1998-12-23 2002-09-17 Rosetta Inpharmatics, Inc. Method and system for analyzing biological response signal data
US6351712B1 (en) 1998-12-28 2002-02-26 Rosetta Inpharmatics, Inc. Statistical combining of cell expression profiles
US6370478B1 (en) 1998-12-28 2002-04-09 Rosetta Inpharmatics, Inc. Methods for drug interaction prediction using biological response profiles
US6222093B1 (en) * 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
DE19860833C1 (de) * 1998-12-30 2000-09-07 Albrecht E Sippel Methode zur zellulären High-Throughput(Hochdurchsatz)-Detektion von Rezeptor-Liganden-Interaktionen
AU2596800A (en) * 1998-12-31 2000-07-31 Iconix Pharmaceuticals, Inc. Method for generating a pathway reporter system
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
WO2000052209A1 (en) * 1999-03-02 2000-09-08 Chiron Corporation Microarrays for identifying pathway activation or induction
AU4186600A (en) * 1999-03-31 2000-10-16 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferation drugs
WO2000058521A2 (en) * 1999-03-31 2000-10-05 Rosetta Inpharmatics, Inc. Methods for the identification of reporter and target molecules using comprehensive gene expression profiles
US6197517B1 (en) 1999-05-21 2001-03-06 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US6221597B1 (en) 1999-05-21 2001-04-24 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US6200803B1 (en) 1999-05-21 2001-03-13 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
WO2000073799A1 (en) 1999-06-01 2000-12-07 Caliper Technologies Corp. Microscale assays and microfluidic devices for transporter, gradient induced, and binding activities
US6673554B1 (en) * 1999-06-14 2004-01-06 Trellie Bioinformatics, Inc. Protein localization assays for toxicity and antidotes thereto
US20040152126A1 (en) * 1999-07-12 2004-08-05 Manuel Fresno Escudero Methods of screening for cox-2 inhibitors
ES2160062B1 (es) * 1999-07-12 2002-05-16 Esteve Labor Dr Linea celular que comprende el promotor de la ciclooxigenasa-2 (cox-2) y un gen testigo y su empleo en la busqueda de inhibidores selectivos de la induccion transcripcional de cox-2.
US7371516B1 (en) 1999-07-16 2008-05-13 Rosetta Inpharmatics Llc Methods for determining the specificity and sensitivity of oligonucleo tides for hybridization
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
US6888951B1 (en) * 1999-08-23 2005-05-03 Nagaoka & Co., Ltd. Methods and apparatus for analyzing operational and analyte data acquired from optical disc
US6673536B1 (en) 1999-09-29 2004-01-06 Rosetta Inpharmatics Llc. Methods of ranking oligonucleotides for specificity using wash dissociation histories
US6403766B1 (en) 1999-10-15 2002-06-11 Cornell Research Foundation, Inc. Human actin regulatory proteins and methods for detection, diagnosis and treatment of different stages of carcinogenesis
JP2004536082A (ja) * 1999-10-22 2004-12-02 グラクソ グループ リミテッド ｉｎｖｉｖｏイメージング
WO2001034810A2 (en) 1999-11-09 2001-05-17 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation
EP1950306A1 (de) 1999-11-17 2008-07-30 Mendel Biotechnology, Inc. Umweltstress-Toleranzgene
BR0015631A (pt) 1999-11-17 2002-07-09 Mendel Biotechnology Inc Planta, polinucleotìdeo, vetor, célula, composição, polipeptìdeo, métodos para produzir uma planta e para identificar um fator que é modulado por, ou interage com, um polipetìdeo codificado por um polinucleotìdeo, uma molécula que module a atividade ou a expressão de um polinucleotìdeo ou polipetìdeo de interesse, e uma sequência similar ou homóloga a um ou mais polinucleotìdeos, e, sistema integrado, meio computadorizado ou legìvel em computador
AU1603701A (en) * 1999-11-19 2001-05-30 Cold Spring Harbor Laboratory Transgenic mice expressing fluorescent protein under the control of the nestin promoter
DE19957065B4 (de) 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening-Verfahren für Arzneistoffe
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
GB0000908D0 (en) * 2000-01-14 2000-03-08 Scient Generics Ltd Parallel free-space optical communications
US6635423B2 (en) * 2000-01-14 2003-10-21 Integriderm, Inc. Informative nucleic acid arrays and methods for making same
GB0001703D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Assay
US6783985B1 (en) 2000-02-18 2004-08-31 Elitra Pharmaceuticals Inc. Gene disruption methodologies for drug target discovery
WO2001066742A2 (en) * 2000-03-03 2001-09-13 Incyte Genomics, Inc. G-protein coupled receptors
US6656695B2 (en) * 2000-03-06 2003-12-02 Bioseek, Inc. Biomap characterization of biologically active agents
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
US7266458B2 (en) * 2000-03-06 2007-09-04 Bioseek, Inc. BioMAP analysis
EP1263988A2 (de) * 2000-03-09 2002-12-11 Yale University Phytomocs: ein genom-basierender ansatz hin zu kräuterzusammensetzungen
US6716582B2 (en) * 2000-04-14 2004-04-06 E. I. Du Pont De Nemours And Company Cellular arrays for the identification of altered gene expression
US6900015B2 (en) 2000-04-24 2005-05-31 Beth Israel Deaconess Medical Center, Inc. Measurement of protective genes in allograft rejection
US6902882B2 (en) 2000-05-23 2005-06-07 Kerong Gu Methods of monitoring production of gene products and uses thereof
WO2002002740A2 (en) 2000-07-05 2002-01-10 Rosetta Inpharmatics, Inc. Methods and compositions for determining gene function
US7244598B2 (en) * 2000-08-14 2007-07-17 Surface Logix, Inc. Biomolecule arrays
EP2410060A1 (de) 2000-08-22 2012-01-25 Mendel Biotechnology, Inc. Gene zum Verändern der Eigenschaften von Pflanzen IV
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US6902933B2 (en) * 2000-11-03 2005-06-07 Regents Of The University Of Michigan Surface transfection and expression procedure
US7572575B2 (en) * 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
CA2327581A1 (en) * 2000-12-27 2002-06-27 Yves Blais Methods and compositions for the establishment of genetically altered cell-based library designed for monitoring transcriptional activity of compounds and molecules
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20020197653A1 (en) * 2001-03-05 2002-12-26 Matthew Shair System for detecting reporter gene expression
AU2002252370A1 (en) * 2001-03-12 2002-09-24 Irm, Llc. Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
IL158488A0 (en) * 2001-04-20 2004-05-12 Sinai School Medicine Tir3 a novel taste receptor
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
EP1390468A4 (de) * 2001-04-23 2004-09-22 Elitra Pharmaceuticals Inc Identifizierung essentieller gene von aspergillus fumigatus und verwendungsverfahren
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
CN100465619C (zh) 2001-06-29 2009-03-04 梅索磅秤技术有限公司 发光测试检测用的检测板、读数系统和方法
US6691042B2 (en) 2001-07-02 2004-02-10 Rosetta Inpharmatics Llc Methods for generating differential profiles by combining data obtained in separate measurements
AUPR631601A0 (en) * 2001-07-11 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Biotechnology array analysis
EP1412487B1 (de) 2001-07-30 2010-06-16 Meso Scale Technologies LLC Assay-elektroden mit schichten aus immobilisiertem lipid/protein sowie verfahren zu deren herstellung und verwendung
EP1448766A2 (de) * 2001-09-27 2004-08-25 University Of Delaware Coisogene eukaryontische zellansammlungen
JP2005522187A (ja) * 2001-10-12 2005-07-28 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア サン ディエゴ 胃腸化学感覚受容体
US20050171923A1 (en) * 2001-10-17 2005-08-04 Harri Kiiveri Method and apparatus for identifying diagnostic components of a system
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20030211538A1 (en) * 2001-12-03 2003-11-13 Ming Luo CAP-Gly domain structure and uses thereof
US20030170694A1 (en) * 2001-12-21 2003-09-11 Daniel Wall Stabilized nucleic acids in gene and drug discovery and methods of use
AU2003209340A1 (en) * 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
US7418351B2 (en) * 2002-01-31 2008-08-26 Rosetta Inpharmatics Llc Methods for analysis of measurement errors in measured signals
WO2003065282A1 (en) * 2002-02-01 2003-08-07 Rosetta Inpharmatics Llc Computer systems and methods for identifying genes and determining pathways associated with traits
US20050240311A1 (en) * 2002-03-04 2005-10-27 Herschel Rabitz Closed-loop apparatuses for non linear system identification via optimal control
AU2002309495A1 (en) * 2002-03-04 2003-09-29 The Trustees For Princeton University Closed-loop apparatuses for non linear system identification via optimal control
US7091331B2 (en) 2002-03-04 2006-08-15 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides encoding baboon TAFI
JP2005527904A (ja) * 2002-05-20 2005-09-15 ロゼッタ インファーマティクス エルエルシー 複雑性疾患を構成疾患に細分するコンピュータ・システムおよび方法
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040128080A1 (en) * 2002-06-28 2004-07-01 Tolley Alexander M. Clustering biological data using mutual information
US20060111849A1 (en) * 2002-08-02 2006-05-25 Schadt Eric E Computer systems and methods that use clinical and expression quantitative trait loci to associate genes with traits
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2004020583A2 (en) * 2002-08-27 2004-03-11 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
US7537891B2 (en) * 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
PT1546336E (pt) 2002-09-18 2012-04-09 Mendel Biotechnology Inc Polinucleótidos e polipéptidos em plantas
CA2494899A1 (en) * 2002-09-27 2004-04-08 Oridis Biomed Forschungs-Und Entwicklungs Gmbh Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
EP1570081A4 (de) * 2002-11-19 2006-05-31 Amgen Inc An krebs beteiligte amplifizierte gene
US20040128081A1 (en) * 2002-12-18 2004-07-01 Herschel Rabitz Quantum dynamic discriminator for molecular agents
US7022481B2 (en) * 2002-12-19 2006-04-04 Rosetta Inpharmatics Llc Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
AU2003303502A1 (en) 2002-12-27 2004-07-29 Rosetta Inpharmatics Llc Computer systems and methods for associating genes with traits using cross species data
WO2004065551A2 (en) * 2003-01-21 2004-08-05 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
US7996155B2 (en) 2003-01-22 2011-08-09 Microsoft Corporation ANOVA method for data analysis
FR2852317B1 (fr) 2003-03-13 2006-08-04 Biopuces a sondes et leurs methodes d'utilisation
EP1628993A4 (de) * 2003-05-16 2010-04-07 Rosetta Inpharmatics Llc Verfahren und zusammensetzungen zur rna-interfrenz
WO2004109447A2 (en) 2003-05-30 2004-12-16 Rosetta Inpharmatics Llc Computer systems and methods for identifying surrogate markers
PT1629088E (pt) 2003-05-30 2012-04-10 Agensys Inc Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas
WO2004113502A2 (en) * 2003-06-20 2004-12-29 Avalon Pharmaceuticals, Inc. Identification of therapeutic agents using genetic fingerprinting
WO2005020886A2 (en) * 2003-06-27 2005-03-10 New England Biolabs, Inc. Identification and use of cofactor independent phosphoglycerate mutase as a drug target
WO2005002527A2 (en) * 2003-07-03 2005-01-13 Massachusetts Institute Of Technology Sirt1 modulation of adipogenesis and adipose function
US20070105114A1 (en) * 2003-07-29 2007-05-10 Martha Li Biomarkers of cyclin-dependent kinase modulation
WO2005012559A1 (en) * 2003-07-30 2005-02-10 Rosetta Inpharmatics Llc Methods of using a sterol biosynthesis pathway reporter gene to screen for antifungal or lipid lowering compounds
US20070038386A1 (en) * 2003-08-05 2007-02-15 Schadt Eric E Computer systems and methods for inferring casuality from cellular constituent abundance data
WO2005017807A2 (en) * 2003-08-13 2005-02-24 Iconix Pharmaceuticals, Inc. Apparatus and method for classifying multi-dimensional biological data
US20050244810A1 (en) * 2003-09-29 2005-11-03 Egan Josephine M Taste signaling in gastrointestinal cells
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005046454A2 (en) 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US20050164969A1 (en) * 2003-11-19 2005-07-28 Massachusetts Institute Of Technology Method of extending life span
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
US20060069049A1 (en) * 2003-12-29 2006-03-30 President And Fellows Of Harvard College Methods and reagents related to foxo
WO2005067667A2 (en) * 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
EP1719051A4 (de) * 2004-02-27 2009-06-17 Bioseek Inc Biologische datensatzprofilierung von asthma und atopie
US7881872B2 (en) * 2004-03-12 2011-02-01 Microsoft Corporation Methods of analyzing multi-channel profiles
JP5223072B2 (ja) 2004-04-02 2013-06-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20070021918A1 (en) * 2004-04-26 2007-01-25 Georges Natsoulis Universal gene chip for high throughput chemogenomic analysis
WO2005107412A2 (en) * 2004-04-30 2005-11-17 Rosetta Inpharmatics Llc Systems and methods for reconstruction gene networks in segregating populations
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
KR101314461B1 (ko) * 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
US7323347B2 (en) * 2004-05-27 2008-01-29 Sensata Technologies, Inc. Biosensor surface structures and methods
MXPA06013834A (es) 2004-05-28 2007-03-01 Agensys Inc Anticuerpos y moleculas relacionadas que enlazan a proteinas psca.
WO2005124650A2 (en) * 2004-06-10 2005-12-29 Iconix Pharmaceuticals, Inc. Sufficient and necessary reagent sets for chemogenomic analysis
ATE551432T1 (de) 2004-06-21 2012-04-15 Univ Leland Stanford Junior Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
US7588892B2 (en) * 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
CN101432001A (zh) 2004-08-20 2009-05-13 巴克年龄研究协会 取代或激动p53功能的小分子
US20060121511A1 (en) * 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US20060271305A1 (en) * 2005-02-25 2006-11-30 The Trustees Of Princeton University Optimal dynamic discrimination of similar molecular scale systems using functional data
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
US8447526B2 (en) * 2005-05-23 2013-05-21 Microsoft Corporation Methods and computer systems for analyzing high-throughput assays
PL3117833T3 (pl) 2005-07-19 2019-06-28 Stemgen S.P.A. Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
TWI333959B (en) * 2005-08-31 2010-12-01 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
WO2007028005A2 (en) 2005-09-01 2007-03-08 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
US7781209B2 (en) 2005-09-25 2010-08-24 Multispan, Inc. GPCR-expressing cell lines
AU2006311827A1 (en) * 2005-11-03 2007-05-18 Redpoint Bio Corporation High throughput screening assay for the TRPM5 ion channel
AU2006311661B2 (en) 2005-11-07 2011-05-26 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
JP5366554B2 (ja) 2005-11-12 2013-12-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー うつを診断および処置するためのｆｇｆ２関連方法
CN103301475B (zh) 2005-12-28 2016-08-03 斯克里普斯研究所 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
US20070198653A1 (en) * 2005-12-30 2007-08-23 Kurt Jarnagin Systems and methods for remote computer-based analysis of user-provided chemogenomic data
US8440622B2 (en) * 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
HUE056086T2 (hu) 2006-03-15 2022-01-28 Brigham & Womens Hospital Inc Gelszolin alkalmazása gyulladásos betegségek diagnosztizálására és kezelésére
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
AU2007227195A1 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and Ly6 E: targets for cancer diagnosis and therapy
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
JP2009532035A (ja) * 2006-03-31 2009-09-10 ブリストル−マイヤーズ スクイブ カンパニー 微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法
WO2007129598A1 (ja) 2006-05-02 2007-11-15 Teikyo University グルタチオン増加物質のスクリーニング方法
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
DE602007013213D1 (de) * 2006-06-06 2011-04-28 Massachusetts Inst Technology Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung
DE602006012460D1 (de) 2006-06-07 2010-04-08 Nutrinova Gmbh Verfahren zum Screening von Substanzen die die Aktivität von Gpcrs modulieren
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US7674594B2 (en) * 2006-07-27 2010-03-09 Redpoint Bio Corporation Screening assay for inhibitors of TRPA1 activation by a lower alkyl phenol
WO2008022035A2 (en) * 2006-08-10 2008-02-21 The Scripps Research Institute Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
JP2010501172A (ja) 2006-08-25 2010-01-21 オンコセラピー・サイエンス株式会社 肺癌に対する予後マーカーおよび治療標的
ES2484142T3 (es) 2006-09-06 2014-08-11 The Regents Of The University Of California Diagnóstico molecular y clasificación del melanoma maligno
US20100021885A1 (en) * 2006-09-18 2010-01-28 Mark Fielden Reagent sets and gene signatures for non-genotoxic hepatocarcinogenicity
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
WO2008073303A2 (en) * 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
AU2007341981A1 (en) * 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
US20100120788A1 (en) * 2007-01-09 2010-05-13 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
WO2008127526A2 (en) * 2007-03-12 2008-10-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
US20080229436A1 (en) * 2007-03-15 2008-09-18 Board Of Trustees Of The University Of Arkansas Methods for identifying modulators of lifespan and resistance to oxidative stress
KR20090128474A (ko) * 2007-04-13 2009-12-15 브리스톨-마이어스 스큅 컴퍼니 혈관 내피 성장인자 수용체-2 조절제에 대한 감수성을 판정하기 위한 방법 및 바이오마커
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CA2687964A1 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2008151289A1 (en) * 2007-06-05 2008-12-11 President And Fellows Of Harvard College Modulating airway inflammation
WO2009009662A1 (en) * 2007-07-10 2009-01-15 University Of South Florida Method of predicting non-response to first line chemotherapy
JP5555626B2 (ja) 2007-08-13 2014-07-23 バクスター・インターナショナル・インコーポレイテッド 多発性硬化症、アルツハイマー病およびパーキンソン病を処置するためのケモカインのｉｖｉｇ調節
CA2702025A1 (en) * 2007-10-01 2009-04-09 Redpoint Bio Corporation A non-desensitizing mutant of the transient receptor potential trpm5 ion channel
JP5496897B2 (ja) 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
WO2011063161A2 (en) 2009-11-20 2011-05-26 The Regents Of The University Of California Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
EP2212693B1 (de) 2007-10-22 2015-04-22 The Regents of The University of California Biomarker für die pränatale diagnose
CA2960659C (en) 2007-11-09 2021-07-13 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
EP2238454A1 (de) * 2008-01-15 2010-10-13 Bristol-Myers Squibb Company Verfahren zur krebsbehandlung bei patienten mit überexpression des brustkrebs-resistenzproteins
HUE032875T2 (en) 2008-01-25 2017-11-28 Massachusetts Gen Hospital Diagnostic and therapeutic applications of gelsolin in renal failure
AU2009332930A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
NZ587750A (en) 2008-03-05 2012-10-26 Univ California Molecular diagnosis and classification of malignant melanoma
AU2009225665B9 (en) 2008-03-17 2015-01-15 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US9884070B2 (en) 2008-04-21 2018-02-06 Lawrence Livermore National Security, Llc Selective high-affinity polydentate ligands and methods of making such
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
EP2352841A2 (de) 2008-09-23 2011-08-10 President and Fellows of Harvard College Sirt4 und verwendungen davon
CN102239260B (zh) 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
US20100169025A1 (en) * 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
WO2010054379A2 (en) 2008-11-10 2010-05-14 The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
AU2009322346B2 (en) 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
CA2745811C (en) 2008-12-04 2021-07-13 Joseph Collard Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
JP6091752B2 (ja) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
US20100233172A1 (en) * 2008-12-16 2010-09-16 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
EP3312269A1 (de) 2008-12-17 2018-04-25 The Scripps Research Institute Erzeugung und erhaltung von stammzellen
US8170805B2 (en) * 2009-02-06 2012-05-01 Syngenta Participations Ag Method for selecting statistically validated candidate genes
US9074210B2 (en) 2009-02-12 2015-07-07 Curna, Inc. Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
US9464287B2 (en) 2009-03-16 2016-10-11 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
MX2011009752A (es) 2009-03-17 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
US20100240065A1 (en) * 2009-03-18 2010-09-23 Boehringer Ingelheim International Gmbh Prolyl Hydroxylase Compositions and Methods of Use Thereof
US20100240069A1 (en) * 2009-03-18 2010-09-23 Boehringer Ingelheim International Gmbh Drug Discovery Assay for Modulators of HIF-Prolyl Hydroxylase Activity
AU2010241947B2 (en) * 2009-03-27 2014-01-16 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
JP5883782B2 (ja) 2009-05-06 2016-03-15 クルナ・インコーポレーテッド 脂質輸送代謝遺伝子に対する天然アンチセンス転写物の抑制による脂質輸送代謝遺伝子関連疾患の治療
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CN102459597B (zh) 2009-05-08 2020-06-30 库尔纳公司 通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病
CA2762369C (en) 2009-05-18 2021-12-28 Joseph Collard Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
EP2432882B1 (de) 2009-05-22 2019-12-25 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
CN103221541B (zh) 2009-05-28 2017-03-01 库尔纳公司 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
ES2629339T3 (es) 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
CA2765700C (en) 2009-06-16 2021-01-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CN102482672B (zh) 2009-06-26 2016-11-09 库尔纳公司 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2456460A4 (de) 2009-07-24 2013-02-20 Univ California Verfahren und zusammensetzungen zur behandlung und prävention von mit avb5-integrin assoziierten krankheiten
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US9234199B2 (en) 2009-08-05 2016-01-12 Curna, Inc. Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
EP2464731B1 (de) 2009-08-11 2016-10-05 CuRNA, Inc. Behandlung von adiponectin (adipoq)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein adiponectin (adipoq)
CA2771102C (en) 2009-08-14 2019-10-15 The Regents Of The University Of California Methods of diagnosing and treating autism
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
EP2467482A4 (de) 2009-08-21 2013-12-11 Curna Inc Behandlung von chip (c-terminus des hsp70-interagierenden proteins)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen chip
CA2771172C (en) 2009-08-25 2021-11-30 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
DK2480669T3 (en) 2009-09-25 2018-02-12 Curna Inc TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011053907A2 (en) * 2009-11-01 2011-05-05 Zenbio, Inc. Human omental mesothelial cells, methods of isolation and uses thereof
JP6025567B2 (ja) 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
WO2011079263A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
RU2611186C2 (ru) 2009-12-29 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
RU2615450C2 (ru) 2009-12-29 2017-04-04 Курна, Инк. Лечение заболеваний, связанных с ядерным респираторным фактором 1(nrf1), путем ингибирования природного антисмыслового транскрипта к nrf1
CN102791862B (zh) 2009-12-31 2017-04-05 库尔纳公司 通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病
US8946181B2 (en) 2010-01-04 2015-02-03 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
WO2011085066A2 (en) 2010-01-06 2011-07-14 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
CA2786535C (en) 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
RU2611192C2 (ru) 2010-01-25 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
WO2011091435A2 (en) 2010-01-25 2011-07-28 Mount Sinai School Of Medicine Methods of treating liver disease
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
EP2539452B1 (de) 2010-02-22 2016-07-27 CuRNA, Inc. Behandlung von durch pyrrolin-5-carboxylat-reduktase 1 (pycr1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für pycr1
ES2657969T3 (es) 2010-04-02 2018-03-07 Curna, Inc. Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3
EP2556160A4 (de) 2010-04-09 2013-08-21 Curna Inc Behandlung von erkrankungen im zusammenhang mit dem fibroblastenwachstumsfaktor 21 (fgf21) mittels hemmung des natürlichen antisense-transkripts gegen fgf21
RU2018110642A (ru) 2010-05-03 2019-02-27 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
WO2011149843A1 (en) 2010-05-24 2011-12-01 Mendel Biotechnology Inc. Novel reporter constructs for compound screening
NO2576784T3 (de) 2010-05-26 2018-04-14
EP3299464B1 (de) 2010-05-26 2019-10-02 CuRNA, Inc. Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
CN109112126A (zh) 2010-06-23 2019-01-01 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
NO2593547T3 (de) 2010-07-14 2018-04-14
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
WO2012074855A2 (en) 2010-11-22 2012-06-07 The Regents Of The University Of California Methods of identifying a cellular nascent rna transcript
CN103459599B (zh) 2010-11-23 2017-06-16 库尔纳公司 通过抑制nanog的天然反义转录物而治疗nanog相关疾病
AU2011349446C1 (en) 2010-12-22 2016-01-21 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP6355555B2 (ja) 2011-04-01 2018-07-11 キアゲン Ｗｎｔ／ｂ−カテニンシグナル伝達経路に関する遺伝子発現シグネチャーおよびその使用
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
RU2620980C2 (ru) 2011-06-09 2017-05-30 Курна, Инк. Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
ES2613808T3 (es) 2011-07-29 2017-05-26 Oncotherapy Science, Inc. Péptido derivado de ERAP1 y uso del mismo
WO2013036403A1 (en) 2011-09-06 2013-03-14 Curna, Inc. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
ES2692546T3 (es) 2011-12-16 2018-12-04 Poseida Therapeutics, Inc. Moduladores TRPC4 para usar en el tratamiento o la prevención del dolor
WO2013123305A1 (en) 2012-02-16 2013-08-22 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
US10105351B2 (en) 2012-03-14 2018-10-23 University Of Central Florida Research Foundation, Inc. Neurofibromatoses therapeutic agents and screening for same
JP2015511494A (ja) 2012-03-15 2015-04-20 キュアナ，インク． 脳由来神経栄養因子（ｂｄｎｆ）に対する天然アンチセンス転写物の阻害によるｂｄｎｆ関連の疾患の処置
US9612235B2 (en) 2012-04-05 2017-04-04 Koch Biological Solutions, Llc Herbicidal compound screening
EP2841450A2 (de) 2012-04-24 2015-03-04 University of Miami Perforin-2-abwehr gegen invasive und multiwirkstoffresistente pathogene
US9347948B2 (en) 2012-06-04 2016-05-24 The Scripps Research Institute Phenyl glyoxal probes
EP3184121A3 (de) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Regelung der interaktion zwischen tam-liganden und lipidmembranen mit exponiertem phosphatidylserin
EP2890370B1 (de) 2012-08-31 2019-10-09 The Regents of the University of California Mittel zur behandlung von adipositas, diabetes und verwandten erkrankungen
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
AU2013334075B2 (en) 2012-10-26 2018-11-29 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
US20140243356A1 (en) 2013-02-07 2014-08-28 The Regents Of The University Of California Use of translational profiling to identify target molecules for therapeutic treatment
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
JP2016518126A (ja) 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ローンスターウイルス
WO2014200905A2 (en) 2013-06-10 2014-12-18 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
EP3041953A4 (de) * 2013-09-03 2017-04-26 Coyne IP Holdings, LLC Verfahren für genetisch diversifizierte stimulus-reaktions-basierte genassoziationsstudien
WO2015057461A2 (en) 2013-10-18 2015-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
EP3079475B1 (de) 2013-12-11 2020-10-07 Sloan-kettering Institute For Cancer Research Glucocorticoid-inhibitoren zur behandlung von prostatakrebs
EP3080122B1 (de) 2013-12-11 2018-10-31 Biogen MA Inc. Zur behandlung von erkrankungen des menschen in der onkologie, neurologie und immunologie geeignete biarylverbindungen
EP3805369A1 (de) 2014-03-04 2021-04-14 Fate Therapeutics, Inc. Verbesserte neuprogrammierungsverfahren und zellkulturplattformen
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
US10196701B2 (en) 2015-06-01 2019-02-05 The Penn State Research Foundation Hepatitis B virus capsid assembly
WO2016209772A2 (en) 2015-06-22 2016-12-29 Proteovista Llc Snp arrays
US10782304B2 (en) 2015-06-24 2020-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for detecting protein-protein interactions
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
EP3596117A4 (de) 2017-03-17 2021-01-13 The Johns Hopkins University Gezielte epigenetische therapie gegen das distale regulatorische element der tgfb2-expression
EP3692073A4 (de) 2017-10-03 2021-05-26 Cedars-Sinai Medical Center Verfahren zum targeting des immuncheckpunkt-pd1-signalwegs zur behandlung von lungenfibrose
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5378603A (en) * 1987-03-30 1995-01-03 Board Of Regents, The University Of Texas System Method and composition for identifying substances which activate transcription of the LDL receptor gene
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
AU632494B2 (en) * 1988-05-20 1993-01-07 F. Hoffmann-La Roche Ag Immobilized sequence-specific probes
WO1990015869A1 (en) * 1989-06-19 1990-12-27 Embryogen Corporation Transgenic skin-testing systems
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
HUT66827A (en) * 1990-09-24 1995-01-30 Brent Screening assays
AU1347292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression of viral genes and other genes
EP0516443A1 (de) * 1991-05-31 1992-12-02 Eli Lilly And Company Vektoren und Verfahren um die Regulation von Apolipoprotein-AI-Synthese zu Testen
ES2111289T5 (es) * 1993-01-21 2005-07-16 President And Fellows Of Harvard College Metodos y kits de diagnostico que emplean promotores de estres en mamiferos para determinar la toxicidad de un compuesto.
US5659024A (en) * 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes

Also Published As

Publication number Publication date
ES2219692T3 (es) 2004-12-01
EP0791078A1 (de) 1997-08-27
CA2202154A1 (en) 1997-02-20
DE69632716D1 (de) 2004-07-22
EP0791078B1 (de) 2004-06-16
DE69632716T2 (de) 2005-07-07
AU724474B2 (en) 2000-09-21
US5569588A (en) 1996-10-29
JPH10507647A (ja) 1998-07-28
CA2202154C (en) 2009-10-27
AU6720996A (en) 1997-03-05
WO1997006277A1 (en) 1997-02-20
DK0791078T3 (da) 2004-10-18

Similar Documents

Publication Publication Date Title
ATE269414T1 (de) Verfahren zur drogenuntersuchung
Nora et al. Segmental folding of chromosomes: a basis for structural and regulatory chromosomal neighborhoods?
Andersson Promoter or enhancer, what's the difference? Deconstruction of established distinctions and presentation of a unifying model
ATE397089T1 (de) Verfahren zum screenen von mehrfach transformierten zellen unter verwendung bicistronischer expression von fluoreszenzproteinen
Lamar et al. Nrarp is a novel intracellular component of the Notch signaling pathway
Putnam et al. Microtubule assembly is regulated by externally applied strain in cultured smooth muscle cells
Ham et al. Spontaneous coordinated activity in cultured networks: analysis of multiple ignition sites, primary circuits, and burst phase delay distributions
Hughey et al. Single-cell variation leads to population invariance in NF-κB signaling dynamics
Hanawalt Revisiting the rodent repairadox
Gaspar et al. The importance of determining circadian parameters in pharmacological studies
DK1143006T3 (da) Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
CA2403817A1 (en) Methods of modulating hair growth
DE60040335D1 (de) Derivatisierte nukleinsäuren und deren verwendung
ATE364721T1 (de) Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden
DE69808060D1 (de) Verfahren zur identifizierung von nukleinsäuren, welche agenzien kodieren, die zelluläre phenotypen beeinflussen
ATE397752T1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
NO20053344D0 (no) Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.
Gimigliano et al. Proteomic profile identifies dysregulated pathways in Cornelia de Lange syndrome cells with distinct mutations in SMC1A and SMC3 genes
ATE357537T1 (de) Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren
Gebhardt et al. Balancing of ephrin/Eph forward and reverse signaling as the driving force of adaptive topographic mapping
Reed et al. Nucleotide excision repair and the ubiquitin proteasome pathway—do all roads lead to Rome?
Goyal et al. A quantitative model of developmental RTK signaling
Albini et al. Histone modifications
Johnstone et al. A novel method for quantifying axon degeneration
He et al. Rpd3 regulates single-copy origins independently of the rDNA array by opposing Fkh1-mediated origin stimulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0791078

Country of ref document: EP